{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-025878","form_type":"8-K","ticker":null,"cik":"0001783032","company_name":"Elevation Oncology, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.838645+00:00","generated_at":"2026-05-24T10:30:09.302864+00:00","sec_items":["2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elevation Oncology halts EO-3021, lays off 70%, initiates strategic review","bullets":["Discontinued lead ADC EO-3021 after Phase 1 data showed 22.2% ORR and 72.2% DCR in biomarker-enriched gastric/GEJ cancer patients.","Reducing workforce by ~70%; estimated $3M in cash costs, majority paid by June 2025. CMO Valerie Jansen departs March 31.","Advancing EO-1022 (HER3 ADC) with glycan site-specific conjugation; IND filing targeted 2026, preclinical data at AACR 2025.","Cash, cash equivalents and securities of $93.2M at Dec 31, 2024 fund operations into 2H 2026.","Evaluating strategic options to maximize shareholder value in parallel with EO-1022 development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-025878","json":"https://secwatch.observer/filing/0001104659-25-025878.json","markdown":"https://secwatch.observer/filing/0001104659-25-025878.md","text":"https://secwatch.observer/filing/0001104659-25-025878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/0001104659-25-025878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/tm259617d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:30:09.302864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9432657905","claim":"Valerie M. Jansen departed as Chief Medical Officer at Elevation Oncology, Inc..","evidence_excerpt":"On March 20, 2025, the Company and Valerie M. Jansen, Chief Medical Officer of the Company, agreed that Dr. Jansen would step down as Chief Medical Officer effective March 31, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/0001104659-25-025878-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"3bedb13da86baf39fb0135bef0ed555af7eddf1b","claim":"Elevation Oncology, Inc. announced a restructuring with charges of approximately $3 million affecting entire company (approximately 70%).","evidence_excerpt":"The total cash payments and costs related to this reduction in force are estimated to be approximately $3 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000110465925025878/0001104659-25-025878-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3 million"},{"label":"Affected area","value":"entire company"},{"label":"Headcount","value":"approximately 70%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}